Morgensztern D - Search Results

1

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR. Owonikoko TK, et al. Among authors: morgensztern d. J Clin Oncol. 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. Epub 2021 Mar 8. J Clin Oncol. 2021. PMID: 33683919 Free PMC article. Clinical Trial.

2

Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.

Morgensztern D, Govindan R. Morgensztern D, et al. Expert Rev Anticancer Ther. 2006 Apr;6(4):545-51. doi: 10.1586/14737140.6.4.545. Expert Rev Anticancer Ther. 2006. PMID: 16613542 Review.

3

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Govindan R, et al. Among authors: morgensztern d. J Clin Oncol. 2006 Oct 1;24(28):4539-44. doi: 10.1200/JCO.2005.04.4859. J Clin Oncol. 2006. PMID: 17008692

4

Second-line therapy for esophageal cancer.

Martin MG, Govindan R, Morgensztern D. Martin MG, et al. Among authors: morgensztern d. Expert Rev Anticancer Ther. 2007 Jun;7(6):871-6. doi: 10.1586/14737140.7.6.871. Expert Rev Anticancer Ther. 2007. PMID: 17555397 Review.

5

Is there a role for cetuximab in non small cell lung cancer?

Morgensztern D, Govindan R. Morgensztern D, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4602-5. doi: 10.1158/1078-0432.CCR-07-0545. Clin Cancer Res. 2007. PMID: 17671149 Review.

6

A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer.

Morgensztern D, Perry MC, Govindan R. Morgensztern D, et al. Acta Oncol. 2008;47(1):152-3. doi: 10.1080/02841860701418853. Acta Oncol. 2008. PMID: 17926147 Clinical Trial. No abstract available.

7

The effect of FDG-PET on the stage distribution of non-small cell lung cancer.

Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R. Morgensztern D, et al. J Thorac Oncol. 2008 Feb;3(2):135-9. doi: 10.1097/JTO.0b013e3181622c2c. J Thorac Oncol. 2008. PMID: 18303433 Free article.

8

EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.

Fong T, Morgensztern D, Govindan R. Fong T, et al. Among authors: morgensztern d. J Thorac Oncol. 2008 Mar;3(3):303-10. doi: 10.1097/JTO.0b013e3181645477. J Thorac Oncol. 2008. PMID: 18317074 Free article. Review.

9

Adjuvant chemotherapy for lung cancer: cisplatin doublets only?

Morgensztern D, Govindan R. Morgensztern D, et al. J Natl Compr Canc Netw. 2008 Mar;6(3):277-84. doi: 10.6004/jnccn.2008.0023. J Natl Compr Canc Netw. 2008. PMID: 18377846

10

Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005.

Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R. Morgensztern D, et al. J Thorac Oncol. 2009 Dec;4(12):1524-9. doi: 10.1097/JTO.0b013e3181ba3634. J Thorac Oncol. 2009. PMID: 19752759 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

164 results

Search Page